OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Curran on the Integration of Immunotherapy With Radiation Therapy in Lung Cancer

March 31st 2020

Walter J. Curran, Jr, MD, FACR, FASCO, explains the eligibility criteria for immunotherapy and radiation in patients with lung cancer.

Dr. Donington on Neoadjuvant Immunotherapy in Lung Cancer

March 31st 2020

Jessica Donington, MD, MSCR, discusses the effectiveness of neoadjuvant immunotherapy and how it compares with neoadjuvant chemotherapy in patients with lung cancer.

Dr. Burtness on the Effectiveness of Immunotherapy in Head and Neck Cancers

March 31st 2020

Barbara Burtness, MD, discusses the effectiveness of immunotherapy in patients with platinum-refractory head and neck cancers.

Dr. Pavlick on Sequencing Challenges in BRAF-Mutant Melanoma Treatment

March 31st 2020

Anna C. Pavlick, DO, discusses sequencing challenges faced in the treatment of patients with BRAF-mutant melanoma.

Dr. Berdeja on Updated Data With bb21217 in Multiple Myeloma

March 31st 2020

Jesus Berdeja, MD, the director of Multiple Myeloma Research at Sarah Cannon Research Institute, discusses updated data with bb21217 in multiple myeloma.

Dr. Soto Perez de Celis on COVID-19 Risk Reduction

March 31st 2020

Enrique Soto Pérez de Celis, MD, MSc, a geriatric oncologist and researcher in the Department of Geriatrics at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán in Mexico City, Mexico, discusses ways to reduce the risk of contracting the novel coronavirus 2019 (COVID-19).

Dr. Vargas on the Utility of Sentinel Node Biopsy in Breast Cancer

March 31st 2020

Hernan Vargas, MD, FACS, a breast surgeon at Virginia Cancer Specialists, discusses the utility of sentinel lymph node biopsy in breast cancer.

Dr. Oh on Results From the PRINT Trial in mCRPC

March 31st 2020

William K. Oh, MD, sheds light on the results of the phase II PRINT trial in metastatic castration-resistant prostate cancer.

Dr. Sartor on Implications of PSMA-PET Positivity in Prostate Cancer

March 31st 2020

A. Oliver Sartor, MD, discusses the implications of prostate-specific membrane antigen-PET positivity in prostate cancer.

Dr. Antonarakis on the Utility of Sipuleucel-T Plus Radium-223 in Nonmetastatic CRPC

March 31st 2020

Emmanuel S. Antonarakis, MBBCh, discusses the utility of sipuleucel-T plus radium-223 in nonmetastatic castration-resistant prostate cancer.

Dr. Chen on the Impact of the Pivotal IMpower133 Trial on SCLC

March 31st 2020

Hui-Zi Chen, MD, PhD, discusses how the IMpower133 trial has helped to propel the field of small-cell lung cancer forward.

Dr. Agarwal on the Safety of Cabozantinib/Atezolizumab in mCRPC

March 31st 2020

Neeraj Agarwal, MD, discusses the safety profile ofcabozantinib and atezolizumab in patients with metastatic castration-resistant prostate cancer.

Using Steroids to Manage Immunotherapy-Associated AEs in Melanoma

March 30th 2020

Kathleen Madden, FNP, MSN, AOCNP, APHN, discusses how to judiciously use steroids to manage adverse events in patients with melanoma who are receiving immunotherapy.

Dr. Schmaier on Managing Thrombosis in Hematologic Malignancies

March 28th 2020

Alvin H. Schmaier, MD, discusses managing thrombosis in patients with hematologic malignancies.

Dr. Radich on the Utility of MRD in Hematologic Malignancies

March 28th 2020

Jerald P. Radich, MD, discusses the utility of minimal residual disease in hematologic malignancies.

Dr. Lonial on the Role of Targeted Therapy in AML and ALL

March 28th 2020

Sagar Lonial, MD, FACP, discusses the role of targeted therapy in acute myeloid leukemia and acute lymphoblastic leukemia.

Dr. de Wit on the AEs With Cabazitaxel in the CARD Trial in mCRPC

March 28th 2020

Ronald de Wit, MD, PhD, group leader, Experimental Systematic Therapy of Urogenital Cancers program, Erasmus MC Cancer Institute, Rotterdam, Netherlands, discusses the adverse events (AEs) with cabazitaxel (Jevtana) in the phase III CARD trial in patients with metastatic castration-resistant prostate cancer (mCRPC).

Dr. Hussain on the Implications of the PROfound Trial in mCRPC

March 28th 2020

Maha Hussain, MD, FACP, FASCO, Genevieve E. Teuton Professor of Medicine in the Division of Hematology and Oncology, Department of Medicine, and Deputy Director at the Robert H. Lurie Comprehensive Cancer Center, of Northwestern University Feinberg School of Medicine, discusses the implications of the phase III PROfound trial in metastatic castration-resistant prostate cancer (mCRPC).

Dr. Parker on the Results of the RADICALS-RT Trial in Prostate Cancer

March 28th 2020

Chris Parker, MD, consultant clinical oncologist, The Royal Marsden NHS Foundation Trust, discusses the results of the phase III RADICALS-RT trial in prostate cancer.

Dr. Garcia on Efficacy of Navitoclax in Ruxolitinib-Resistant Myelofibrosis

March 28th 2020

Jacqueline S. Garcia, MD, discusses results from a phase II trial examining the addition of the BCL-2/BCL-XL inhibitor navitoclax to ruxolitinib in patients with primary or secondary myelofibrosis with acquired resistance to ruxolitinib.